{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Astrana Health, Inc.
Astrana Health, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Astrana Health, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, priced at $33.30, has shown significant volatility over the past year, with a high of $60.99 and a low of $21.20. Technical indicators present a mixed outlook, reflecting ongoing recovery efforts.
Is Astrana Health, Inc. overvalued or undervalued?
As of October 17, 2025, Astrana Health, Inc. is considered very expensive with a P/E ratio of 36, significantly higher than its peers, and has underperformed the S&P 500 with a year-to-date return of 1.52% and a one-year return of -47.84%.
Astrana Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Astrana Health, Inc. has recently adjusted its valuation, with its stock price at $32.01. The company has faced a notable decline in stock performance over the past year, contrasting with broader market gains. Key financial metrics indicate a higher valuation compared to peers, reflecting differing market perceptions.
Is Astrana Health, Inc. overvalued or undervalued?
As of October 17, 2025, Astrana Health, Inc. is considered very expensive and overvalued, with a P/E ratio of 36 and an EV to EBITDA ratio of 14.41, alongside a one-year return of -47.84% compared to the S&P 500's 14.08% gain.
Is Astrana Health, Inc. overvalued or undervalued?
As of October 17, 2025, Astrana Health, Inc. is considered very expensive with a high P/E ratio of 36 and significant overvaluation compared to peers, despite a recent 9.96% one-week return, as it has declined 47.84% over the past year while the S&P 500 gained 14.08%.
Is Astrana Health, Inc. technically bullish or bearish?
As of August 8, 2025, Astrana Health, Inc. shows a mildly bearish trend overall, with mixed technical indicators across time frames and significant underperformance compared to the S&P 500.
Is Astrana Health, Inc. overvalued or undervalued?
As of July 7, 2025, Astrana Health, Inc. is considered very expensive with a high P/E ratio of 36 and underperformance against the S&P 500, indicating it is overvalued compared to its peers and industry standards.
Is Astrana Health, Inc. overvalued or undervalued?
As of February 27, 2025, Astrana Health, Inc. is considered very expensive and overvalued with a P/E ratio of 36, significantly higher than peers like Select Medical Holdings Corp. at 7.26 and Premier, Inc. at 14.00, while also showing low returns on capital and equity, and underperforming the S&P 500 by 39.25% over the past year.
Is Astrana Health, Inc. technically bullish or bearish?
As of May 30, 2025, Astrana Health, Inc. is in a bearish trend, indicated by negative signals from MACD, KST, and moving averages, along with mildly bearish conditions from Bollinger Bands and Dow Theory, suggesting a prevailing market weakness.
Who are in the management team of Astrana Health, Inc.?
As of March 2022, the management team of Astrana Health, Inc. includes Dr. Kenneth Sim (Chairman and Co-CEO), Dr. Thomas Lam (President and Co-CEO), and several directors including Mr. Mitchell Kitayama (Lead Independent Director), Ms. Linda Marsh, Mr. Matthew Mazdyasni, Dr. Ernest Bates, and Mr. John Chiang. They oversee the company's operations and strategic direction.
What does Astrana Health, Inc. do?
Astrana Health, Inc. is a physician-centric integrated population health management company with net sales of $620 million and a net profit of $6 million as of March 2025. It has a market cap of approximately $1.48 billion and key metrics include a P/E ratio of 36.00 and a debt-to-equity ratio of 0.22.
How big is Astrana Health, Inc.?
As of Jun 18, Astrana Health, Inc. has a market capitalization of 1,475.48 million, with net sales of 2,250.57 million and a net profit of 39.29 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
